NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis

Clinical Nephrology

Volumn 73, Issue 3, 2010, Pages 180-189

  Al Shahrouri, H Z ^a   Ramirez, P ^a   Fanti, P ^a   Abboud, H ^a   Lorenzo, C ^b   Haffner, S ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Atherogenic lipids; Diabetic nephropathy

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALBUMINURIA; ARTICLE; ATHEROGENESIS; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC NEPHROPATHY; DISORDERS OF LIPOPROTEIN METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE;

EID: 77649242320     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73180     Document Type: Article

References (37)

1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White H, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351: 1285-1295.
2. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int. 2003; 63 (Suppl 84): S207-S210.
3. Coresh J, Astor B, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12.
4. de Boer IH, Astor BC, Kramer H, Palmas W, Rudser K, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B. Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethic Study of Atherosclerosis (MESA). Atherosclerosis. 2008; 197: 407-414.
5. de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B. Lipoprotein abnormalities associated with mild impairment of kidney function in the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol. 2008; 3: 125-132.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA. 2001; 285: 2486-2497.
7. Farbakhsh K, Kasiske BL. Dyslipidemia in patients who have chronic kidney disease. Med Clin North Am. 2005; 89: 689-699.
8. Fellström BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-1407.
9. Festa A, D'Agostino R Jr, Mykkänen L, Tracy RP, Hales CN, Howard BV, Haffner SM. Low density lipoprotein particle size (LDL) in relation to insulin, proinsulin, and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999; 22: 1688-1693.
10. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation. 2005; 111: 3465-3472
11. Gatling W, Knight C, Mullee MA, Hill RD. Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabet Med. 1988; 5: 343-347.
12. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein R, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003; 52: 453-462.
13. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetics and nondiabetic individuals. JAMA. 2001; 286: 421-426.
14. Go AS, Chertow GN, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
15. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis. 1995; 26: 152-161.
16. Jenkins AJ, Lyon TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. Lipoprotein in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney Int. 2003; 64: 817-828.
17. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006; 26: 847-870.
18. Keulen ET, Kruijshoop M, Schaper NC, Hoeks AP, de Bruin TW. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Thromb Vasc Biol. 2002; 22: 283-288.
19. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982; 23: 97-104.
20. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Bensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987; 8550: 62-66.
21. Kroll MH, Chesler R, Hagengruber C, Blank DW, Kestner J, Rawe M. Automated determination of urinary creatinine without sample dilution: theory and practice. Clin Chem. 1986; 32: 446-452.
22. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G, Lupien P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. Circulation. 1997; 95: 69-75.
23. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Arterioscler Thromb Vasc Biol. 1997; 17: 64-71.
24. Levey AS, Green T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine (Abstract). J Am Soc Nephrol. 2000; 11: 155A.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985; 28: 412-419.
26. Molitch ME. Management of dyslipidemia in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1: 1090-1099.
27. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes. Arandomized placebo-controlled trial. Lancet. 2003; 361: 2006-2016.
28. National Kidney Foundation, Kidney Disease Outcome Quality Initiative (K/DOQI). Clinical Practice Guidelines for Managing Dyslipidemia in Chronic Kidney Disease; 2003.
29. Ritz E, Wanner C. Lipid Abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol. 2008; 19: 1065-1070.
30. Sandhu S, Wiebe N, Fried L, Tonelli M. Statin for improving renal outcomes: Ameta-analysis. J Am Soc Nephrol. 2006; 17: 2006-2016.
31. Sniderman AD, Holme I, Aastveit AH, Furberg C, Walldius G, Jungner I. Relation of age, the apolipoprotein B/ apolipoprotein A-I Ratio, and the risk of fatal myocardial Infarction and implications for the primary prevention of cardiovascular disease. Am J Cardiol. 2007; 100: 217-221.
32. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004; 110: 1557-1563.
33. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study):a prospective study. Lancet. 2001; 358: 2026-2033.
34. Wheeler DC, Nair DR, Persaud JW, Jeremy JY, Chappell ME, Varghese Z, Moorhead JF. Effects of dietary fatty acids in an animal model of focal glomerulosclerosis. Kidney Int. 1991; 39: 930-937.
35. Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF, Bergman RN, Hamman R. The Insulin Resistance Atherosclerosis Study (IRAS): Objectives, design, and recruitment results. Ann Epidemiol. 1995; 5: 464-472.
36. Wanner C. Altered lipid metabolism and serum lipids in renal disease and renal failure. In: Kopple and Massry's Nutritonal Management of Renal Disease. Los Angeles: Lippincott Williams and Wilkins; 2003. Chapter 3: p. 41-60.
37. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 53: 238-248.